Wells Fargo & Company Veracyte, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Veracyte, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 93,059 shares of VCYT stock, worth $2.66 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
93,059
Previous 96,375
3.44%
Holding current value
$2.66 Million
Previous $2.14 Million
5.57%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding VCYT
# of Institutions
254Shares Held
82.1MCall Options Held
42.3KPut Options Held
18.2K-
Black Rock Inc. New York, NY7.79MShares$223 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.5MShares$214 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA6.88MShares$196 Million0.03% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.81MShares$195 Million1.34% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.46MShares$98.9 Million0.02% of portfolio
About VERACYTE, INC.
- Ticker VCYT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,575,904
- Market Cap $2.04B
- Description
- Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...